Privium Fund Management B.V. Grows Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Privium Fund Management B.V. boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 7.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 80,232 shares of the company's stock after acquiring an additional 5,900 shares during the quarter. Axsome Therapeutics accounts for about 1.8% of Privium Fund Management B.V.'s portfolio, making the stock its 16th largest position. Privium Fund Management B.V. owned 0.17% of Axsome Therapeutics worth $7,210,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Axsome Therapeutics in the second quarter worth approximately $27,000. EntryPoint Capital LLC acquired a new position in shares of Axsome Therapeutics in the 1st quarter worth approximately $35,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Axsome Therapeutics in the 2nd quarter valued at $47,000. Russell Investments Group Ltd. boosted its stake in shares of Axsome Therapeutics by 5,550.0% in the 1st quarter. Russell Investments Group Ltd. now owns 791 shares of the company's stock valued at $63,000 after purchasing an additional 777 shares during the last quarter. Finally, Covestor Ltd increased its position in shares of Axsome Therapeutics by 54,750.0% during the first quarter. Covestor Ltd now owns 1,097 shares of the company's stock worth $88,000 after buying an additional 1,095 shares during the period. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $107.00 price objective on shares of Axsome Therapeutics in a research report on Monday, September 16th. Bank of America raised Axsome Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $95.00 to $106.00 in a report on Tuesday, August 6th. HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Axsome Therapeutics in a research note on Thursday, September 5th. Needham & Company LLC reiterated a "buy" rating and issued a $130.00 target price on shares of Axsome Therapeutics in a research note on Thursday, September 5th. Finally, StockNews.com raised Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, Axsome Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $124.64.

Insiders Place Their Bets

In other news, Director Mark E. Saad sold 11,016 shares of the company's stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the transaction, the director now directly owns 10,002 shares of the company's stock, valued at $913,282.62. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 22.40% of the company's stock.

Axsome Therapeutics Stock Down 0.7 %

Shares of Axsome Therapeutics stock traded down $0.63 during trading on Friday, reaching $90.07. The company's stock had a trading volume of 635,290 shares, compared to its average volume of 364,163. The company has a quick ratio of 2.40, a current ratio of 2.48 and a debt-to-equity ratio of 1.77. The company has a market cap of $4.28 billion, a price-to-earnings ratio of -13.84 and a beta of 1.26. The company has a 50-day simple moving average of $90.31 and a two-hundred day simple moving average of $83.62. Axsome Therapeutics, Inc. has a 1-year low of $55.02 and a 1-year high of $98.40.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.